Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma

Oncotarget

Volumn 6, Issue 28, 2015, Pages 26508-26518

  Bi, Chonglei ^a,b   Chung, Tae Hoon ^a   Huang, Gaofeng ^a   Zhou, Jianbiao ^a   Yan, Junli ^a   Ahmann, Gregory J ^c   Fonseca, Rafael ^c   Chng, Wee Joo ^a,b,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c MAYO CLINIC   (United States)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Epigenetics MicroRNA; Myeloma; Tumor suppressor

Indexed keywords

MICRORNA; MICRORNA 125A 3P; MICRORNA 135A; MICRORNA 155; MICRORNA 188 5P; MICRORNA 198; MICRORNA 200C; MICRORNA 483 5P; MICRORNA 630; MICRORNA 663; UNCLASSIFIED DRUG; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; TUMOR MARKER;

ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; MULTIPLE MYELOMA; RNA ANALYSIS; ANTAGONISTS AND INHIBITORS; BIOLOGY; CELL MOTION; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM; MORTALITY; PATHOLOGY; PHENOTYPE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICRORNAS; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS;

EID: 84944462954     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4769     Document Type: Article

References (54)

1. Chng WJ, Lau LG, Yusof N and Mow BM. Targeted therapy in multiple myeloma. Cancer Control. 2005; 12:91- 104.
2. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF and Melton LJ, 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002; 346:564-569.
3. Kuehl WM and Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002; 2:175-187.
4. Chesi M and Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol. 2013; 97:313-323.
5. Garzon R, Calin GA and Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009; 60:167-179.
6. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F and Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99:15524-15529.
7. Spizzo R, Nicoloso MS, Croce CM and Calin GA. SnapShot: MicroRNAs in Cancer. Cell. 2009; 137:586-586 e581.
8. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA and Jones PA. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006; 9:435-443.
9. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F and Garcia-Foncillas J.Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009; 125:2737-2743.
10. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Jr., Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010; 18:367-381.
11. Wong KY, Yim RL, So CC, Jin DY, Liang R and Chim CS. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood. 2011; 118:5901-5904.
12. Wong KY, Liang R, So CC, Jin DY, Costello JF and Chim CS. Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol. 2011; 154:569-578.
13. Jones PA, Taylor SM and Wilson VL. Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res. 1983; 84:202-211.
14. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008; 105:12885-12890.
15. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, Ferminan E, Martin-Jimenez P, Chillon C, Risueno A, Hernandez JM, Garcia-Sanz R, Gonzalez M and San Miguel JF. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010; 24:629-637.
16. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, et al. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res. 2013; 19:3130-3142.
17. Wang L, Shi M, Hou S, Ding B, Liu L, Ji X, Zhang J and Deng Y. MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett. 2012; 586:1312-1317.
18. Pan J, Hu H, Zhou Z, Sun L, Peng L, Yu L, Sun L, Liu J, Yang Z and Ran Y. Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells. Oncology reports. 2010; 24:105-112.
19. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupe P, Robert T, Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E and Kroemer G. miR-181a and miR-630 regulate cisplatininduced cancer cell death. Cancer Res. 2010; 70:1793-1803.
20. Jones PA and Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999; 21:163-167.
21. Kulis M and Esteller M. DNA methylation and cancer. Adv Genet. 2010; 70:27-56.
22. Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA and Salum FG. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer. 2011; 117:677-687.
23. Koerner MV, Pauler FM, Hudson QJ, Santoro F, Sawicka A, Guenzl PM, Stricker SH, Schichl YM, Latos PA, Klement RM, Warczok KE, Wojciechowski J, Seiser C, Kralovics R and Barlow DP. A downstream CpG island controls transcript initiation and elongation and the methylation state of the imprinted Airn macro ncRNA promoter. PLoS genetics. 2012; 8:e1002540.
24. Shaughnessy JD, Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007; 109:2276-2284.
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545-15550.
26. Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, Zielinski CC, Drach J and Zochbauer-Muller S. Genome-wide transcriptional response to 5-aza-2'- deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res. 2008; 68:44-54.
27. Kanehisa M, Goto S, Sato Y, Furumichi M and Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012; 40(Database issue):D109-114.
28. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010; 116:2543-2553.
29. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Jr., Bergsagel PL, Schenkein D, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007; 109:3177-3188.
30. Krzeminski P, Sarasquete ME, Misiewicz-Krzeminska I, Corral R, Corchete LA, Martin AA, Garcia-Sanz R, San Miguel JF and Gutierrez NC. Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. Biochimica et Biophysica Acta. 2015; 1849:353- 366.
31. Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR, Shidham A and Croce CM. Src homology 2 domain containing inositol-5-phosphatase and CCAAT enhancerbinding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 2009; 114:1374- 1382.
32. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth- Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY and Cheng JQ. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014; 33:679-689.
33. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007; 104:16170-16175.
34. Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, Yan M, Qu QL, Zhu ZG and Liu BY. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncology reports. 2012; 27:1960-1966.
35. Qin W, Ren Q, Liu T, Huang Y and Wang J. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 2013; 587:1434-1439.
36. Levati L, Pagani E, Romani S, Castiglia D, Piccinni E, Covaciu C, Caporaso P, Bondanza S, Antonetti FR, Bonmassar E, Martelli F, Alvino E and D'Atri S. MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment cell & melanoma research. 2011; 24:538-550.
37. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B and Shaughnessy J, Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005; 106:296-303.
38. Santarius T, Shipley J, Brewer D, Stratton MR and Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 2010; 10:59-64.
39. Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC and Carrasco DR. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 2009; 69:7577-7586.
40. Holt RU, Fagerli UM, Baykov V, Ro TB, Hov H, Waage A, Sundan A and Borset M. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica. 2008; 93:619-622.
41. Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE and Morgan GJ. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 2009; 94:78-86.
42. Min DJ, Ezponda T, Kim MK, Will CM, Martinez-Garcia E, Popovic R, Basrur V, Elenitoba-Johnson KS and Licht JD. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia. 2013; 27:686-694.
43. Zhang W, Wang YE, Zhang Y, Leleu X, Reagan M, Zhang Y, Mishima Y, Glavey S, Manier S, Sacco A, Jiang B, Roccaro AM and Ghobrial IM. Global epigenetic regulation of microRNAs in multiple myeloma. PLoS One. 2014; 9:e110973.
44. Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D'Aquila P, Di Martino MT, Calimeri T, Rossi M, Lionetti M, Leone E, Passarino G, Neri A, Giordano A, Tagliaferri P and Tassone P. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 2013; 12:3650-3662.
45. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gulla AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P and Tassone P. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget. 2012; 3:1246-1258.
46. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolino FM, Del Giudice T, Iuliano E, Caraglia M, Ferrarini M, Giordano A, Tagliaferri P and Tassone P. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 2013; 228:1506-1515.
47. Zhang YK, Wang H, Leng Y, Li ZL, Yang YF, Xiao FJ, Li QF, Chen XQ and Wang LS. Overexpression of microRNA- 29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. Biochem Biophys Res Commun. 2011; 414:233-239.
48. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gulla AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Disease. 2012; 3:e436.
49. Zhou JB, Bi CL, Janakakumara JV, Liu SC, Chng WJ, Tay KG, Poon LF, Xie ZG, Palaniyandi S, Yu H, Glaser KB, Albert DH, Davidsen SK and Chen CS. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009; 113:4052-4062.
50. Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, Bi C, Tan J, Kwong YL, Shimizu N, Aozasa K and Chng WJ. Dysregulated microRNAs affect pathways and targets of biological relevance in nasal-type natural killer/T-cell lymphoma. Blood. 2011; 118:4919-4929.
51. Reghunathan R, Bi C, Liu SC, Loong KT, Chung TH, Huang G and Chng WJ. Clonogenic multiple myeloma cells have shared stemness signature assocuated with patient survival. Oncotarget. 2013; 4:1230-1240.
52. Maksimovic J, Gordon L and Oshlack A. SWAN: Subsetquantile within array normalization for illumina infinium HumanMethylation450 BeadChips. Genome biology. 2012; 13:R44.
53. Xiao F, Zuo Z, Cai G, Kang S, Gao X and Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009; 37(Database issue):D105-110.
54. Dweep H, Sticht C, Pandey P and Gretz N. miRWalk-- database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform. 2011; 44:839-847.